赛立奇单抗治疗中重度斑块状银屑病的疗效观察OA

Objective To assess the therapeutic effectiveness and safety profile of Xeligekimab in patients with moderate-to-severe psoriasis.Methods Thirty-eight patients with moderate-to-se-vere plaque psoriasis were enrolled.Patients received subcutaneous injections of Xeligekimab(200 mg)once every 2 weeks during the first 12 weeks,followed by once every 4 weeks for a total treatment duration of 16 weeks.The psoriasis area and severity index(PASI),physician global assessment(PGA),and dermatology life quality index(DLQI)were evaluated at baseline and at weeks 4,8,12,and 16.Adverse reactions were recorded throughout the study.Results Thirty-seven patients completed the 16-week follow-up,while one patient withdrew due to injection-site reactions and personal reasons.At week 16,the response rates for PASI 75,PASI 90,and PASI 100 were 100％,86.49％,and 59.46％,respectively.The proportion of patients achieving a PGA score of 0 or 1 was 97.30％.The DLQI score improved significantly from a baseline of 13.49±5.81 to 0.51±0.90 at week 16.No serious adverse reactions occurred in any of the 37 patients.Conclusion Xeligekimab significantly improves skin lesions and quality of life in patients with moderate-to-severe plaque psoriasis,demonstrating a favorable overall safety profile.